Bayer Aims For Global OTC Lead With Bolt-On Acquisition Plans
This article was originally published in The Tan Sheet
Executive Summary
Chairman Marijn Dekkers says the German company believes strong organic growth and consumer health pick-ups will help Bayer become the world leader in OTCs.
You may also be interested in...
Bayer Buys Merck Consumer Biz, Aiming For Top Of Global OTC Industry
The $14.2 billion deal is “a major milestone on our path toward global leadership” in OTC sales, says Bayer Chairman Marijn Dekkers. The acquisition focuses on expanding international sales of Merck products including the Coppertone sunscreen, Claritin allergy and MiraLax constipation lines.
Bayer Lands Merck Consumer As Springboard to Lead Global OTC Industry
The $14.2 billion deal is “a major milestone on our path toward global leadership” in OTC sales, says Bayer Chairman Marijn Dekkers. The acquisition focuses on expanding international sales of Merck products including the Claritin allergy, Coppertone sunscreen and MiraLax constipation lines.
Bayer Lands Merck Consumer As Springboard to Lead Global OTC Industry
The $14.2 billion deal is “a major milestone on our path toward global leadership” in OTC sales, says Bayer Chairman Marijn Dekkers. The acquisition focuses on expanding international sales of Merck products including the Claritin allergy, Coppertone sunscreen and MiraLax constipation lines.